Clinical Trial Search

Primary: Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) — 6.70; 6.22; 8.46 score on a…

Primary: Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score — -2.40; -1.97 units on a scale — p=0.030

Primary: Number of Participants With Incorrect Duration of Use of the Medication — 97; 89 Participants

Primary: AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity) — 10500; 12400; 12600; 17500 nmol*h/L

Primary: Change From Baseline in Number of Accurate Responses to Rapid Visual Information Processing (RVIP) Cognitive Test — 8.3; 4.8; 4.5; 2.7 Correct responses — p=0.0248

Primary: Central Cornea Endothelial Cell Loss — 11.78; 13.03; 12.05; 7.77 % of endothelial cell loss

Primary: Safety of Tympanostomy Tube (TT) Delivery System — 0.0 percentage of ears

Primary: Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T]) — 14.04; 23.81; 40.51…

Primary: Subject Reported Target Lesion Severity Score. — 4.0 units on a scale

Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…

Primary: Assessment of Immediate Post-injection Pain Severity by Subject — 6.3; 2.0 units on a scale

Primary: Headache Relief (Modified LOCF - Efficacy Evaluable Analysis Set) — 42; 30 Participants

Primary: Efficacy of IV Ibuprofen for Post-op Pain. — 8; 34; 19; 41 units on a scale

Primary: Percentage of Participants With Clinical Success — 85; 69 percentage of participants — p=0.009

Primary: Percent Change From Baseline in Plasma Deacylated Globotriaosylceramide (Lyso-GL-3) at Month 2, 4 and 6 — -31.71; -39.04; -39.54 percent change — p=0.0002